Table 4. Treatment-related mortality... | American Society of Hematology

Table 4.

Treatment-related mortality

Cohort	Any CGVHD		Lim, ext		Mild, mod, sev		Low, int, high
Cohort	RR^4-150	95% CI	RR^4-150	95% CI	RR^4-150	95% CI	RR^4-150	95% CI
IBMTR-1	1.8^4-151	(1.3-2.4)	0.7^4-155	(0.5-1.2)	0.6^4-155	(0.4-1.0)	0.6^4-155	(0.3-0.9)
			2.7	(2.0-3.7)	1.9^4-155	(1.4-2.8)	2.2^4-153	(1.5-3.2)
					6.3	(4.4-9.0)	4.2	(2.9-6.0)
IBMTR-2	2.8^4-151	(1.9-4.1)	1.0^4-155	(0.6-1.9)	1.0^‡	(0.5-1.8)	1.4^4-155	(0.8-2.3)
			4.5	(3.0-6.7)	2.1^4-153	(1.3-3.5)	3.9	(2.4-6.4)
					10.9	(7.0-16.9)	5.2	(3.2-8.5)
NMDP	1.8^4-151	(1.4-2.4)	1.4	(0.9-2.3)	N/A		0.8	(0.5-1.5)
			1.9	(1.4-2.5)			1.4^‡	(0.9-2.1)
							2.4	(1.5-3.7)

Cohort	Any CGVHD		Lim, ext		Mild, mod, sev		Low, int, high
Cohort	RR^4-150	95% CI	RR^4-150	95% CI	RR^4-150	95% CI	RR^4-150	95% CI
IBMTR-1	1.8^4-151	(1.3-2.4)	0.7^4-155	(0.5-1.2)	0.6^4-155	(0.4-1.0)	0.6^4-155	(0.3-0.9)
			2.7	(2.0-3.7)	1.9^4-155	(1.4-2.8)	2.2^4-153	(1.5-3.2)
					6.3	(4.4-9.0)	4.2	(2.9-6.0)
IBMTR-2	2.8^4-151	(1.9-4.1)	1.0^4-155	(0.6-1.9)	1.0^‡	(0.5-1.8)	1.4^4-155	(0.8-2.3)
			4.5	(3.0-6.7)	2.1^4-153	(1.3-3.5)	3.9	(2.4-6.4)
					10.9	(7.0-16.9)	5.2	(3.2-8.5)
NMDP	1.8^4-151	(1.4-2.4)	1.4	(0.9-2.3)	N/A		0.8	(0.5-1.5)
			1.9	(1.4-2.5)			1.4^‡	(0.9-2.1)
							2.4	(1.5-3.7)

For abbreviations see Table 3.

F4-150

Adjusted for disease type (acute myelogenous leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia), disease stage (early, intermediate, advanced), age (years), patient-donor sex matching, and presence of prior acute GVHD (yes, no).

F4-151

P ≤ .0001 compared with no cGVHD.

‡

P ≤ .01 compared with next most severe category.

F4-153

P ≤ .001 compared with next most severe category.

F4-155

P ≤ .0001 compared with next most severe category.

View Large